Matt Abernethy
Chief Financial Officer at Neurocrine Biosciences; Board Member at Fate Therapeutics
- Role
- Chief Financial Officer at Neurocrine Biosciences
- Location
- San Diego, CA, US
- LinkedIn followers
- 500 followers
About Matt Abernethy
Matthew Abernethy is the Chief Financial Officer at Neurocrine Biosciences, a neuroscience-focused biopharmaceutical company. Mr. Abernethy has 15 years of experience in the financial sector and investor relations with expertise in the healthcare industry, leading corporate finance activities and commercial supply chain operations, as well as information technology and investor relations functions.Mr. Abernethy joined Neurocrine from Zimmer Biomet, where he held various positions from February 2009 to November 2017, including most recently, Vice President, Investor Relations and Treasurer and Vice President of Finance for the Americas and Global Product Engines. He began his career with KPMG LLP and is a certified public accountant. Mr. Abernethy earned a B.S. in Accounting and Business Administration from Grace College and an M.B.A. from the University of Chicago.
Experience
Chief Financial Officer
Nov 2017 — Present · San Diego, CA, US
Education
The University of Chicago Booth School of Business
Master of Business Administration (M.B.A.)
2013 — 2015
Grace College & Seminary
Bachelor of Science - BS, Accounting and Business/Management
2000 — 2003
Skills
- Financial Modeling
- Internal Controls
- Sec Filings
- Forecasting
- Financial Analysis
- Corporate Finance
- Sarbanes-Oxley Act
- Us Gaap
- Due Diligence
- Process Improvement
- Cost Accounting
- Cross-Functional Team Leadership
- Finance
- Mergers & Acquisitions
- Consolidation
- Financial Reporting
Find verified contacts for anyone on LinkedIn
Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.
Free plan included · No credit card required
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.